borderline significancep = 0.07
Additionally, IGF1R mutations exhibited borderline significance (7.2% vs. 2.9%, p = 0.07).
Additionally, IGF1R mutations exhibited borderline significance (7.2% vs. 2.9%, p = 0.07).
Regarding the diagnostic group, patients with primary tumors without axillary involvement showed a trend toward reduced recurrence risk (OR = 0.19, 95% CI: 0.03–1.47, p = 0.070), consistent with the expectation that localized disease has a more favorable prognosis.
Although alterations in PI3K, TGF-Beta, and RTK/RAS pathways were not statistically significant, borderline significance was observed in genes related to these pathways, including EGFR ( p = 0.07), FGFR1 ( p = 0.05), FGFR2 ( p = 0.05), and PTPN11 ( p = 0.05) in the PI3K pathway and SMAD4 ( p = 0.08) in the TGF-Beta pathway.
The test for subgroup differences showed a trend toward statistical significance ( p = 0.07), thus no strong evidence of differential effects based on the method used to define sarcopenia was observed ( Supplementary File S6 ). - Overall survival (multivariate analyses, aHR): In the subgroup analysis for OS based on multivariate regression analyses’ reported outcomes, the pooled aHR for the 29 studies defining sarcopenia using SMI was 1.59 (1.40; 1.80), with substantial heterogeneity (I 2 = 79%, τ 2 = 0.06, p < 0.01).
CDX2 was near statistical significance for DFS (HR = 2.15, 95% CI (0.92–5.04), p = 0.070).
Other hemodynamic parameters showed only borderline significance (cumulative time of reduced heart rate: p = 0.0706; mean systolic blood pressure during surgery: p = 0.0844; oxygen saturation: p = 0.0719; mean heart rate p = 0.0937).
There was a statistical trend in OS ( p = 0.071) and PFS ( p = 0.053) for both cohorts.
An analysis of OS showed a trend toward statistical significance with decreased TTAC (HR 1.004 [0.9997–1.0084]; p = 0.071).
The analysis to recognize a predictive prognostic value for miRNA dysregulation showed a trend toward significance (overexpression of miRNA–221, p = 0.071).
Despite most of the samples with high expression of ID4 were from patients older than 50 (73.5%), this association was marginally significant ( p = 0.071).
Regarding the EFS, none of the analyzed factors remained significant in the multivariate analysis but PLS3 had the strongest impact and was borderline significant ( p = 0.071, HR 1.39 (CI 0.97–2.09)).
The LDHA expression of A-498 was also higher than that of UOK262 tumors, with a p -value approaching significance (400 ± 51% vs. 280 ± 43%, p = 0.071) ( Figure 3 B). 2.3.
Tumor necrosis factor alpha (TNFα) levels were higher in BCW12OFS mice compared to BCW0 mice ( p = 0.009) and approached significance compared to BCW12 ( p = 0.071) ( Figure 11 C).
These responders demonstrated a clear trend toward longer OS compared with the non-responders (36.7 vs. 21.5 months, p = 0.071).
Dysphagia grade III six months after treatment showed a trend toward worse survival ( p = 0.071).
The results showed a trend of increased ROS levels (two-tailed unpaired t -test, p = 0.0715) in nerolidol-treated cells when compared to control cells ( Figure S2A ).
When adjusted for confounders, the use of the kit was associated with a nearly significant survival benefit: hazard ratio 0.85 (95% confidence interval: 0.71-1.02, p = 0.0716).
The presence of a pathogenic somatic myeloid mutation was not a risk factor for a CVE for patients receiving imatinib at the time of the CVE (OR 1.9, p = 0.409) but was of borderline significance for patients receiving a 2G-TKI at the time of the CVE (OR 3.11, p = 0.072; Supplementary Table S3 ).
Despite a strong trend in the same direction, CTNNB1 mutations showed no statistically significant association with higher hazard ratio (HR) of PSA progression (HR 2.12, p = 0.072) [ 24 ].
IHC analysis for p-MAPK, a downstream target of FGFR4, in RMS559 tumors found that p-MAPK was suppressed in mice treated with futibatinib compared to vehicle (approaching significance, p = 0.072; Figure A6 ).
An improvement in OS was also noted to be trending towards significance with the use of Osimertinib compared to erlotinib/gefitinib (not reached vs. 20.9 months, p = 0.0725) [ 27 ].
There was a borderline significant association between neoantigen expression and the HER2 status ( p = 0.073).
Post-hoc analyses splitting the groups 2 by 2 showed a trend between controls/IA and colon cancers in Weighted UniFrac ( p = 0.073) ( Figure 3 D). 2.3.
In univariate analysis, patients with MTS-like cancers showed a trend toward improved survival compared to those with other malignancies ( p = 0.073; Supplementary Table S9 and Supplementary Figure S4A ), although this did not reach statistical significance and was not confirmed in multivariable Cox regression (HR 1.2, 95% CI 0.53–2.7; Figure 5 A).
In addition, under criterion 1, nodal status was significant, and tumor size demonstrated a trend toward significance ( p = 0.073).